- prochlorperazine
-
- $30.00 / 1kg
-
2024-01-18
- CAS:58-38-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 6000
- Prochlorperazine
-
- $15.00 / 1KG
-
2021-07-13
- CAS:58-38-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Prochlorperazine Basic information |
| Product Name: | Prochlorperazine | | Synonyms: | n-(gamma-(4’-methylpiperazinyl-1’)propyl)-3-chlorophenothiazine;N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine;n-[gamma-(4’-methylpiperazinyl-1’)propyl]-3-chlorophenothiazine;Nipodal;Phenothiazine, 2-chloro-10-[3-(1-methyl-4-piperazinyl)propyl]-;Chloromeprazine;3-Chloro-10-chlorperazine;10-[3-(4-Methylpiperazino)propyl]-2-chloro-10H-phenothiazine | | CAS: | 58-38-8 | | MF: | C20H24ClN3S | | MW: | 373.94 | | EINECS: | 200-379-4 | | Product Categories: | COMPAZINE;Organics | | Mol File: | 58-38-8.mol |  |
| | Prochlorperazine Chemical Properties |
| Melting point | 228 °C | | Boiling point | 260-275 °C(Press: 2 Torr) | | density | 1.1679 (rough estimate) | | refractive index | 1.6000 (estimate) | | storage temp. | Refrigerator | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) | | form | Solid | | pka | pKa 8.1(H2O,t =24±1,I undefined) (Uncertain) | | color | White to Yellow | | Water Solubility | 14.96mg/L(24 ºC) | | BCS Class | 2 | | CAS DataBase Reference | 58-38-8(CAS DataBase Reference) | | NIST Chemistry Reference | Prochlorperazine(58-38-8) |
| | Prochlorperazine Usage And Synthesis |
| Uses | antiemetic, antipsychotic, treatment of vertigo | | Uses | Prochlorperazine is antiemetic, antipsychotic; used in treatment of vertigo. | | Definition | ChEBI: A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. | | Brand name | Compazine (GlaxoSmithKline). | | Clinical Use |
Nausea and vomiting
Labyrinthine disorders
Psychoses
Severe anxiety | | Safety Profile | Poison by ingestion,
subcutaneous, intravenous, and
intraperitoneal routes. Experimental
teratogenic and reproductive effects. Human
systemic effects by ingestion: headache,
blood pressure elevation. Implicated in
aplastic anemia. When heated to
decomposition it emits very toxic fumes of
SOx, NOx, and Cl-. | | Veterinary Drugs and Treatments | Prochlorperazine as a single agent is used in dogs and cats as an antiemetic.
The only approved products for animals are combination
products containing prochlorperazine, isopropamide, with or without
neomycin (Darbazine?, Neo-Darbazine?—SKB Labs) which
are no longer marketed in the USA. The approved indications for
these products include: vomiting, non-specific gastroenteritis, drug
induced diarrhea, infectious diarrhea, spastic colitis, and motion
sickness in dogs and cats (injectable product only). | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative
effects with opioids; increased risk of ventricular
arrhythmias with methadone.
Anti-arrhythmics increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval, e.g. procainamide, disopyramide,
dronedarone and amiodarone - avoid with
amiodarone and dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with delamanid and moxifloxacin -
avoid.
Antidepressants: increase concentrations and
additive antimuscarinic effects, notably with
tricyclics; increased risk of ventricular arrhythmias
with citalopram and escitalopram - avoid; increased
risk of convulsions with vortioxetine.
Antiepileptics: antagonised (convulsive threshold
lowered).
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias with droperidol and pimozide - avoid;
increased risk of ventricular arrhythmias with
risperidone.
Antivirals: concentration possibly increased with
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid.
Anxiolytics and hypnotics: increased sedative effects.
Atomoxetine: increased risk of ventricular
arrhythmias.
Beta-blockers: enhanced hypotensive effect;
increased risk of ventricular arrhythmias with sotalol.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Desferrioxamine: avoid concomitant use.
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects
and possibly neurotoxicity.
Pentamidine: increased risk of ventricular
arrhythmias. | | Metabolism | Prochlorperazine undergoes extensive first pass
metabolism in the gut wall. It is also extensively
metabolised in the liver and is excreted in the urine and
bile. The metabolites are inactive. |
| | Prochlorperazine Preparation Products And Raw materials |
|